Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2013-06-03 Investor Presentation
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
VGX-100 Phase 1 oncology trial presented at ASCO 2013 3 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is an ASX and media release dated 4 June 2013, reporting on the progress and presentation of a Phase 1 oncology clinical trial of VGX-100 at the ASCO 2013 Annual Meeting. It includes detailed scientific and clinical trial information, study design, objectives, and interim clinical updates. The document is a public announcement of clinical trial progress and presentation at a conference, not a full financial or regulatory report. It does not contain financial statements, audit information, or regulatory certifications. It is a detailed investor and media update on clinical trial progress and scientific data presentation. Therefore, it fits best as an Investor Presentation (IP) type document, as it focuses on detailed information for investors about the company's clinical development and progress.
2013-06-03 English
Change of Director's Interest Notice 3 pages 391.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including number of shares held before and after the change, nature of the transaction, and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives. The document is not an announcement of a report, nor a full financial or management report. It is a regulatory filing specifically about insider trading disclosures.
2013-05-26 English
Open Briefing 3 pages 246.9KB
Investor Presentation Classification · 95% confidence The document is an open briefing interview dated 24 May 2013, discussing the development and clinical potential of VGX-300 by Circadian Technologies Limited. It includes detailed discussion of clinical development strategy, market potential, pre-clinical and clinical trial plans, funding adequacy, and timelines for drug development. The content is a detailed presentation of company strategy, financial status, and product pipeline aimed at investors and stakeholders. It is not a formal financial report, audit, or regulatory filing, nor is it a transcript of a conference call or an announcement of voting results or dividends. The document fits the description of an Investor Presentation (IP) as it focuses on financials, strategy, and market position in detail. The length (over 10,000 characters) and substantive content support this classification with high confidence.
2013-05-23 English
Change of Director's Interest Notice 3 pages 391.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the change, and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an annual report, earnings release, or any other financial report type. It is specifically a notification of a director's change in shareholding. Therefore, the correct classification is DIRS.
2013-05-22 English
Change of Director's Interest Notice 3 pages 377.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion. The document length is 3764 characters, which is consistent with a detailed director's dealing notice. Therefore, the appropriate classification is Director's Dealing (DIRS).
2013-05-19 English
Progress of VGX-100 Phase 1 trial to be presented at ASCO 2 pages 100.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 17 May 2013 announcing that clinical progress of a Phase 1 trial for VGX-100 will be presented at the ASCO 2013 Annual Meeting. It includes details about the presentation, the study, and company background. There are no financial statements, detailed financial analysis, or regulatory filings. The document is a public announcement about clinical trial progress and an upcoming presentation at a scientific conference. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report itself but an announcement of clinical progress and presentation details. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-05-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.